Showing results (891-900 of 931) with videos related to

Sort By:
Pageof 94
Clinical Science (London, England : 1979)|July 30, 2020
Obeticholic acid ameliorates hepatorenal syndrome in ascitic cirrhotic rats by down-regulating the renal 8-iso-PGF2α-activated COX-TXA2 pathwayYu-Lien Tsai, Chih-Wei Liu, Chien-Fu Hsu, et al.
BMJ Open|December 30, 2023
Changing epidemiology, microbiology and mortality of bloodstream infections in patients with haematological malignancies before and during SARS-CoV-2 pandemic: a retrospective cohort studyLinjing Cai, Huan Chen, Yongqiang Wei, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 10, 2017
Effects and mechanisms of caffeine to improve immunological and metabolic abnormalities in diet-induced obese ratsChih-Wei Liu, Hung-Cheng Tsai, Chia-Chang Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2023
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III TrialYiwen Ling, Li Xuan, Na Xu, et al.
Blood Cancer Journal|December 7, 2021
Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomesSijian Yu, Tong Lin, Danian Nie, et al.
British Journal of Haematology|May 21, 2025
Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort studyYiling Ye, Xinyu Liu, Huajuan Dai, et al.
Journal of Hematology & Oncology|April 29, 2023
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 TrialHua Jin, Yu Zhang, Sijian Yu, et al.
The Lancet. Haematology|July 6, 2023
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trialLi Xuan, Yu Wang, Kaibo Yang, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 26, 2017
Serum adrenomedullin and urinary thromboxane B<sub>2</sub> help early categorizing of acute kidney injury in decompensated cirrhotic patients: A prospective cohort studyChih-Wei Liu, Chia-Chang Huang, Hung-Cheng Tsai, et al.
Experimental Hematology & Oncology|July 9, 2025
Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trialKe Zhao, Ren Lin, Zhiping Fan, et al.
Pageof 94